mHSPC KOL Commentaries - mHSPC KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE Case study mHSPC: A Clinical Case StudyJordan Ciuro & Atish Choudhury VIEW MORE KOL Commentary Updates in mHSPC ASCO Genitourinary Symposium 2023Atish Choudhury & Jordan Ciuro VIEW MORE KOL Commentary Novel therapeutic strategies that are helping HCPs manage patients and improving outcomesWilliam Oh VIEW MORE Infographics - mHSPC Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer VIEW INFOGRAPHIC Intensifying Metastatic Hormone-Sensitive Prostate Cancer Treatment VIEW INFOGRAPHIC Articles - mHSPC Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial READ MORE Treatment options for metastatic hormone-sensitive prostate cancer READ MORE Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy READ MORE Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk READ MORE Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer READ MORE Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer READ MORE Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial READ MORE Facebook Twitter Linkedin
